Low back pain and radicular pain : development of a clinical pathway : Supplement

Abstract

97 p.ill.,1. COMPOSITION OF EXPERTS GROUPS 8 -- 1.1. LIST OF PARTICIPANTS TO THE WORKING GROUPS 8 -- 1.2. COMPOSITION OF THE STAKEHOLDERS GROUP 10 -- 1.3. COMPOSITION OF THE SUBCONTRACTOR’S EXPERT TEAM (KULEUVEN) 11 -- 1.4. COMPOSITION OF THE KCE EXPERT TEAM 11 -- 2. LITERATURE REVIEW 12 -- 2.1. DATABASES AND DATE LIMITS 12 -- 2.2. SEARCH STRATEGIES 12 -- 3. EXTRACTS OF THE LIME SURVEY 27 -- 4. DESCRIPTION OF THE PATHWAYS (INTERNATIONAL COMPARISON) 29 -- 4.1. GRONINGEN, THE NETHERLANDS 29 -- 4.1.1. Demographic information 29 -- 4.1.2. Identification and organizational items 29 -- 4.1.3. Patient Selection: 29 -- 4.1.4. Team composition and team members role 30 -- 4.1.5. Evidence and implementation process 31 -- 4.1.6. Triage and diagnosis 31 -- 4.1.7. Therapeutic actions 31 -- 4.1.8. Additional patient items 33 -- 4.1.9. Additional caregiver items 33 -- 4.1.10. Pathway monitoring 33 -- 4.2. NIJMEGEN, THE NETHERLANDS 34 -- 4.2.1. Demographic information 34 -- 4.2.2. Identification and organizational items 34 -- 4.2.3. Patient Selection: 34 -- 4.2.4. Team composition and team members role 35 -- 4.2.5. Evidence and implementation process 36 -- 4.2.6. Triage and diagnosis 36 -- 4.2.7. Therapeutic actions 36 -- 4.2.8. Additional patient items 38 -- 4.2.9. Additional caregiver items 38 -- 4.2.10. Pathway monitoring 38 -- 4.3. MAASTRICHT, THE NETHERLANDS 39 -- 4.3.1. Demographic information 39 -- 4.3.2. Identification and organizational items 39 -- 4.3.3. Patient Selection: 39 -- 4.3.4. Team composition and team members role 39 -- 4.3.5. Evidence and implementation process 40 -- 4.3.6. Triage and diagnosis 40 -- 4.3.7. Therapeutic actions 40 -- 4.3.8. Additional patient items 42 -- 4.3.9. Additional caregiver items 42 -- 4.3.10. Pathway monitoring 42 -- 4.4. SASKATCHEWAN, CANADA 43 -- 4.4.1. Demographic information 43 -- 4.4.2. Patient Selection: 43 -- 4.4.3. Team composition and team members role 43 -- 4.4.4. Evidence and implementation process 44 -- 4.4.5. Triage and diagnosis 44 -- 4.4.6. Therapeutic actions 45 -- 4.4.7. Additional patient items 45 -- 4.4.8. Additional caregiver items 45 -- 4.4.9. Pathway monitoring 45 -- 4.5. TORONTO, CANADA 46 -- 4.5.1. Demographic information 46 -- 4.5.2. Identification and organizational items 46 -- 4.5.3. Patient Selection: 46 -- 4.5.4. Team composition and team members role 47 -- 4.5.5. Evidence and implementation process 48 -- 4.5.6. Triage and diagnosis 48 -- 4.5.7. Therapeutic actions 48 -- 4.5.8. Additional patient items 49 -- 4.5.9. Additional caregiver items 49 -- 4.5.10. Pathway monitoring 49 -- 4.6. NORTH-EAST ENGLAND, UK 50 -- 4.6.1. Demographic information 50 -- 4.6.2. Patient Selection: 50 -- 4.6.3. Team composition and team members role 50 -- 4.6.4. Evidence and implementation process 51 -- 4.6.5. Triage and diagnosis 51 -- 4.6.6. Therapeutic actions 52 -- 4.6.7. Additional patient items 52 -- 4.6.8. Additional caregiver items 52 -- 4.6.9. Pathway monitoring 52 -- 4.7. LONDON (IMPLEMENTATION OF THE BRITISH PAIN SOCIETY PATHWAY), UK 53 -- 4.7.1. Demographic information 53 -- 4.7.2. Patient Selection: 53 -- 4.7.3. Team composition and team members role 53 -- 4.7.4. Evidence and implementation process 54 -- 4.7.5. Triage and diagnosis 54 -- 4.7.6. Therapeutic actions 55 -- 4.7.7. Additional patient items 56 -- 4.7.8. Additional caregiver items 56 -- 4.7.9. Pathway monitoring 56 -- 4.8. IRELAND, WATERFORD 57 -- 4.8.1. Demographic information 57 -- 4.8.2. Identification and organizational items 57 -- 4.8.3. Patient Selection: 57 -- 4.8.4. Team composition and team members role 57 -- 4.8.5. Evidence and implementation process 58 -- 4.8.6. Triage and diagnosis 58 -- 4.8.7. Therapeutic actions 58 -- 4.8.8. Additional patient items 59 -- 4.8.9. Additional caregiver items 59 -- 4.8.10. Pathway monitoring 59 -- 4.9. LAUSANNE, SWITZERLAND 60 -- 4.9.1. Demographic information 60 -- 4.9.2. Identification and organizational items 60 -- 4.9.3. Patient Selection: 60 -- 4.9.4. Team composition and team members role 60 -- 4.9.5. Evidence and implementation process 61 -- 4.9.6. Triage and diagnosis 61 -- 4.9.7. Therapeutic actions 62 -- 4.9.8. Additional patient items 63 -- 4.9.9. Additional caregiver items 63 -- 4.9.10. Pathway monitoring 64 -- 4.10. NÜRNBERG, GERMANY 64 -- 4.10.1. Demographic information 64 -- 4.10.2. Identification and organizational items 64 -- 4.10.3. Patient Selection: 64 -- 4.10.4. Team composition and team members role 64 -- 4.10.5. Evidence and implementation process 65 -- 4.10.6. Triage and diagnosis 65 -- 4.10.7. Therapeutic actions 66 -- 4.10.8. Additional patient items 67 -- 4.10.9. Additional caregiver items 67 -- 4.10.10. Pathway monitoring 67 -- 4.11. PLYMOUTH, UNITED STATES 68 -- 4.11.1. Demographic information 68 -- 4.11.2. Identification and organizational items 68 -- 4.11.3. Patient Selection: 68 -- 4.11.4. Team composition and team members role 68 -- 4.11.5. Evidence and implementation process 70 -- 4.11.6. Triage and diagnosis 70 -- 4.11.7. Therapeutic actions 70 -- 4.11.8. Additional patient items 70 -- 4.11.9. Additional caregiver items 70 -- 4.11.10. Pathway monitoring 71 -- 5. PATHWAYS FLOWCHARTS (INTERNATIONAL COMPARISON) 72 -- 6. BELGIAN INITIATIVES IN FLOWCHARTS 81 -- 7. FOCUS GROUPS MATERIAL 87 -- 7.1. FLYERS FOR PATIENTS 87 -- 7.2. INTERVIEW GUIDE 8